Mestinon (Pyridostigmine)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Symptomatic treatment of myasthenia gravis (Mestinon — oral) | Adults with autoimmune myasthenia gravis (also widely used off-label in paediatric MG) | Symptom-control monotherapy or in combination with immunosuppression / immunomodulation | FDA Approved (1955) |
| Reversal of nondepolarising neuromuscular blockade (Regonol — IV) | Adults recovering from rocuronium, vecuronium, pancuronium, or curare-class anaesthesia | Single-use reversal at end of surgical procedure, with concurrent atropine or glycopyrrolate | FDA Approved |
| Pretreatment against soman nerve agent poisoning (105 mg ER tablet — military) | Adult military personnel at risk of soman (GD) exposure; for use only with protective garments and post-exposure atropine + 2-PAM | Pretreatment monotherapy; not effective if taken at the time of or after exposure | FDA Approved (Military Use Only) |
Pyridostigmine bromide is a reversible cholinesterase inhibitor first approved by the FDA in 1955 and one of the oldest agents still in routine clinical use. It increases the concentration of acetylcholine at the neuromuscular junction by reversibly inhibiting acetylcholinesterase, thereby improving muscle strength in disorders of impaired neuromuscular transmission. The molecule is a quaternary ammonium compound and therefore does not readily cross the blood–brain barrier — this is why it is preferred over physostigmine when only peripheral cholinergic activity is wanted, and why central nervous system effects are generally limited at therapeutic doses. Mestinon remains the cornerstone first-line symptomatic therapy for autoimmune myasthenia gravis. Regonol (IV) is one of several anticholinesterase reversal agents used at the end of surgical anaesthesia to terminate nondepolarising neuromuscular blockade. The 105 mg extended-release tablet, originally approved in 2003 and relabelled in 2024, is a separate FDA-approved product for military use only, intended as pretreatment before exposure to the chemical nerve agent soman; it carries a boxed warning specifically about improper use.
Postural orthostatic tachycardia syndrome (POTS) — pyridostigmine 30–60 mg PO three times daily is sometimes used as adjunctive therapy in neurogenic POTS, particularly in patients with prominent cholinergic dysfunction or as second-line after fludrocortisone, beta-blockers, and ivabradine. Evidence is largely from small open-label and crossover studies. Evidence quality: low to moderate.
Lambert–Eaton myasthenic syndrome (LEMS) — pyridostigmine has been used historically as add-on symptom-control therapy in LEMS, although amifampridine (3,4-diaminopyridine) is the FDA-approved first-line agent. Evidence quality: low (small case series).
Chronic constipation and post-operative ileus — used occasionally in motility disorders, particularly when neostigmine is unsuitable for outpatient use; evidence is limited. Evidence quality: low.
Paediatric myasthenia gravis (juvenile and congenital) — although the FDA label states that paediatric safety and effectiveness have not been established, pyridostigmine is widely used in paediatric MG under specialist supervision and is recommended in international consensus guidance. Evidence quality: moderate (long clinical experience and consensus).
Dosing
Dose is highly individualised — the FDA prescribing information for Mestinon explicitly states that the size and frequency of dosing must be adjusted to the needs of the individual patient. Dosing is titrated to symptom control while avoiding cholinergic toxicity, and timing of doses is often arranged around meals and high-effort activities. The three Mestinon formulations (60 mg IR tablet, 60 mg/5 mL oral solution, and 180 mg Timespan ER tablet) are not directly interchangeable on a milligram-for-milligram basis: the immediate effect of one 180 mg ER tablet is approximately equal to that of one 60 mg IR tablet, but its duration averages about 2.5 times longer.
Myasthenia Gravis — Oral (Mestinon)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| MG — typical adult, immediate-release | 60 mg PO TID–QID | 600 mg/day (≈ ten 60 mg tablets) spaced across the day | 1,500 mg/day (severe disease) | Time doses around meals and demanding activities (e.g., 30–60 min before meals to improve chewing/swallowing) FDA PI: average dose ten 60 mg tablets daily; severe cases up to 25 tablets/day; mild cases 1–6 tablets/day |
| MG — mild disease | 60 mg PO BID–TID | 60–360 mg/day | — | Some patients with ocular or mild generalised disease are well-controlled at the lower end of the range |
| MG — bulbar / brittle / paediatric | Oral solution 60 mg/5 mL | Titrate to effect | — | Solution allows fractional dosing for children and patients with bulbar involvement (easier swallowing); contains 5% alcohol — relevant in young children and patients avoiding alcohol |
| MG — overnight or prolonged-action coverage | Mestinon Timespan 180 mg PO | 180–540 mg once or twice daily | Per FDA PI: 1–3 tablets once or twice daily | Minimum 6-hour interval between ER doses (per FDA PI); often given at bedtime to ease morning weakness; may be combined with regular IR tablets during the day ER 180 mg ≈ same immediate effect as IR 60 mg; duration averages 2.5× longer |
Reversal of Nondepolarising Neuromuscular Blockade — Intravenous (Regonol)
| Clinical Scenario | Pyridostigmine Dose | Companion Atropine / Glycopyrrolate | Onset / Duration | Notes |
|---|---|---|---|---|
| End-of-surgery reversal of nondepolarising neuromuscular blockade | 0.10–0.25 mg/kg IV slow push | Atropine 0.6–1.2 mg IV (or equipotent glycopyrrolate) before/with pyridostigmine | Full recovery typically within 30 min per FDA PI | Use a peripheral nerve stimulator to confirm adequacy of reversal; therapeutic index ~ 1:6 (reversal:blocking) per FDA PI Regonol contains benzyl alcohol — not for use in neonates |
Soman Nerve Agent Pretreatment — Oral 105 mg ER (Military Use Only)
| Clinical Scenario | Dose | Timing | Maximum Duration | Notes |
|---|---|---|---|---|
| Pretreatment for anticipated soman exposure (military personnel) | 105 mg PO once daily | Start ≥ several hours before exposure; continue per command direction | Re-evaluate use beyond 14 consecutive days | Take with a medium-fat / medium-calorie meal (~ 650 kcal, 40% fat) or high-fat / high-calorie meal (~ 1,000 kcal, 50% fat); do not take fasting or with low-fat meals; do not co-administer with alcohol At first sign of nerve agent poisoning: STOP pyridostigmine, don protective mask, give atropine + 2-PAM |
Population-Specific Considerations
| Population | Adjustment | Rationale |
|---|---|---|
| Renal impairment | Reduce dose; titrate to effect; monitor renal function | Pyridostigmine is mainly excreted unchanged by the kidney. In anephric patients (n = 4), elimination half-life increased 3-fold and systemic clearance decreased by ~75% (FDA PI Section 12.3) |
| Geriatric (≥ 65 years) | Cautious dose selection; consider monitoring renal function | Systemic plasma clearance was 30% lower in elderly subjects (71–85 yr) vs younger subjects (21–51 yr); older patients also more likely to have decreased renal, hepatic, or cardiac function and concomitant drug therapy (FDA PI Section 8.5) |
| Hepatic impairment | No specific guidance; use clinical judgment | No specific PK information available in hepatic impairment; clearance is partly hepatic (FDA PI Section 12.3) |
| Pediatric MG | FDA: not established; specialist-supervised off-label use is standard practice | The Mestinon and PB ER labels both state safety and effectiveness in pediatric patients have not been established. International consensus practice in juvenile and congenital MG uses the oral solution titrated by weight |
For myasthenia gravis, ask the patient when their weakness is worst and target dosing accordingly: 30–60 minutes before meals if chewing or swallowing is impaired; before scheduled exertion; and an evening Timespan dose if morning weakness is a problem. The IR tablet typically takes effect within 30–60 minutes and lasts ~3–6 hours; the 180 mg ER tablet acts faster than expected at first (its initial release is similar to a 60 mg IR dose) and then provides a longer tail. Avoid rigid every-4-hour scheduling — symptom-led dosing is safer and more effective. Patients should not double a dose to “catch up”; both under- and overdosing can present as weakness and the distinction (myasthenic vs cholinergic crisis) is clinically critical.
Two extended-release pyridostigmine products are FDA-approved but have completely different indications: Mestinon Timespan 180 mg is the long-standing once- or twice-daily formulation used as an adjunct in myasthenia gravis. The 105 mg pyridostigmine bromide ER tablet (Amneal, relabelled 2024) is for U.S. military use only as soman nerve-agent pretreatment, carries a boxed warning, and must be taken with a medium- or high-fat meal. Do not substitute one for the other; verify product, strength, and indication on every order.
Pharmacology
Mechanism of Action
Pyridostigmine bromide is a reversible carbamate inhibitor of acetylcholinesterase. By temporarily occupying the active site of the enzyme, it reduces the breakdown of acetylcholine released into the synaptic cleft, thereby raising acetylcholine concentrations at neuromuscular and autonomic cholinergic synapses. In myasthenia gravis — where pathogenic autoantibodies reduce the number or function of postsynaptic acetylcholine receptors at the neuromuscular junction — the increased acetylcholine concentration improves the probability of effective receptor activation and transient improvement in muscle strength. The drug’s molecular structure is dominated by a permanently charged quaternary ammonium group, which makes it a polar molecule with poor passive diffusion across lipid membranes; in particular, pyridostigmine does not enter the central nervous system in significant amounts, so its peripheral cholinergic effects predominate over central effects at therapeutic doses. The same quaternary structure underlies its low oral bioavailability (10–20%) and the rationale for its use as a soman pretreatment: a sub-anaesthetic, peripherally acting fraction of acetylcholinesterase is reversibly carbamylated and protected from irreversible inhibition by soman, so that some functional enzyme is preserved when the carbamate dissociates after the threat passes.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability 10–20% (poor); 105 mg ER Tmax ~10 h with medium-fat meal, ~16 h with high-fat meal; high-fat meal increases AUC ~ 3-fold vs fasted state | Oral doses are much higher than IV doses (typical PO 60 mg vs IV ~5–10 mg); ER absorption depends on meal composition — never take ER products fasting |
| Distribution | Vd ~ 19 ± 12 L; quaternary ammonium cation — does not appreciably cross the blood–brain barrier; protein binding not characterised | Peripheral cholinergic effects dominate; central nervous system effects (headache, vertigo) are uncommon and mild at therapeutic doses |
| Metabolism | Hydrolysis by cholinesterases plus hepatic metabolism | Not a substrate for the major CYP450 isoenzymes — relatively few classical pharmacokinetic drug interactions (most clinically relevant interactions are pharmacodynamic) |
| Elimination | Renal excretion of unchanged drug plus metabolites; systemic clearance ~ 830 mL/min. Half-life depends strongly on route and formulation: ~ 5.6 h after the oral 105 mg ER tablet (per 2024 FDA PI); ~ 200 min (3.3 h) after oral IR per Breyer-Pfaff 1985; ~ 97–112 min after IV in patients with normal renal function per Breyer-Pfaff 1985 and Cronnelly 1980. In anephric patients (n = 4), t½ rose ~ 3-fold and CL fell by ~ 75% | Substantial renal clearance — dose reduction is required in chronic kidney disease and elderly patients with impaired renal function. The “flip-flop” appearance of a longer apparent half-life after the ER tablet reflects absorption-rate-limited elimination, not a slower true elimination phase |
Both pyridostigmine and neostigmine are quaternary-ammonium reversible cholinesterase inhibitors used in myasthenia gravis and neuromuscular block reversal. Compared with neostigmine, pyridostigmine has a longer duration of action and a generally lower incidence of muscarinic side effects (notably bradycardia, salivation, and gastrointestinal stimulation). These differences make pyridostigmine the preferred chronic oral therapy in myasthenia gravis, while neostigmine is more commonly chosen for IV reversal of neuromuscular blockade (although both are used in this setting).
Side Effects
Most adverse effects of pyridostigmine are predictable extensions of its cholinergic pharmacology and divide into muscarinic (smooth-muscle / glandular hyperactivity — gastrointestinal, secretory, bradycardia, miosis) and nicotinic (skeletal-muscle hyperexcitability — fasciculations, cramps, weakness) effects. The Mestinon FDA prescribing information (originally approved 1955) provides only qualitative descriptions of adverse effects; controlled-trial frequency data are available primarily from the modern 2024 prescribing information for the 105 mg extended-release tablet (soman pretreatment), based on a 21-day study of immediate-release pyridostigmine 30 mg every 8 hours in healthy volunteers (n = 60 vs 30 placebo). Those frequency figures are summarised below as the closest available source of controlled incidence data; clinical experience in chronic myasthenia gravis suggests that gastrointestinal effects (cramping, diarrhoea, increased salivation) are the most common cause of dose limitation.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| No adverse reaction occurred at ≥ 10% in the controlled study reported in the FDA prescribing information for pyridostigmine 105 mg ER (n = 60). The Mestinon FDA PI does not provide controlled-trial frequency data for the myasthenia gravis indication. | ||
| Adverse Effect | Incidence (Pyridostigmine) | Clinical Note |
|---|---|---|
| Diarrhoea | 7% | Placebo 0%; muscarinic effect; usually dose-related and improves with dose adjustment |
| Abdominal pain | 7% | Placebo 0%; muscarinic; commonly accompanies cramps and increased peristalsis |
| Dysmenorrhoea | 5% | Placebo 0%; smooth-muscle stimulation |
| Twitch / fasciculation | 3% | Placebo 0%; nicotinic effect; if widespread or severe, suggests excessive dose |
| Myalgia | 2% | Placebo 0%; muscle aching; differentiate from worsening MG |
| Dry skin | 2% | Placebo 0% |
| Urinary frequency | 2% | Placebo 0%; bladder smooth-muscle contraction |
| Epistaxis | 2% | Placebo 0% |
| Amblyopia (vision change) | 2% | Placebo 0%; usually transient blurred vision from miosis or accommodative spasm |
| Hypaesthesia / neck pain | 2% each | Placebo 0%; non-specific |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Cholinergic crisis (overdose) | Rare with appropriate dosing; risk increases at > 600 mg/day or in renal impairment | Within hours of overdose | Stop pyridostigmine; secure airway and ventilatory support; IV atropine 1–4 mg, repeated q 5–30 min as needed for muscarinic symptoms; supportive care; recognise that nicotinic skeletal-muscle effects (including respiratory paralysis) are not relieved by atropine |
| Bronchospasm / exacerbation of asthma or COPD | Reported (frequency not quantified) | During therapy, especially with rapid dose escalation | Hold dose; bronchodilator therapy; review whether anticholinesterase therapy is necessary in severe pulmonary disease |
| Bradycardia / cardiac arrhythmias | Mean HR decrease 4–6 bpm; symptomatic bradycardia uncommon at therapeutic doses | During therapy; higher risk in patients on beta-blockers or with sick sinus syndrome | Atropine 0.5–1 mg IV for symptomatic bradycardia; review concomitant negative-chronotropic drugs |
| Hypersensitivity / bromide skin rash | Occasional; usually subsides on discontinuation | Days to weeks of therapy | Discontinue pyridostigmine; consider non-bromide cholinesterase inhibitor (no oral US alternative); supportive treatment |
| Loss of consciousness (rarely seizure-like) | Two reports during safety studies of immediate-release pyridostigmine 30 mg q8h (per FDA PI Section 6.1) | During therapy | Discontinue and seek immediate medical evaluation; one of the two cases included urinary/faecal incontinence and post-event confusion suggesting a seizure event |
| Hypertensive response | Reported (frequency not quantified) | During therapy | Monitor BP especially in patients with cardiovascular disease; usually transient |
| Reason to Reduce Dose or Discontinue | Incidence | Context |
|---|---|---|
| Increasing weakness on stable or rising dose | Per protocol | Could indicate either myasthenic crisis (need more therapy) or cholinergic crisis (need less); urgent specialist evaluation, do not empirically increase the dose |
| Persistent severe gastrointestinal toxicity | Per protocol | Reduce dose, divide into smaller more frequent doses, take with food, or add a peripherally-acting antimuscarinic (e.g., glycopyrrolate) |
| Bromide skin rash | Per protocol | Discontinue and reassess; rash usually subsides on stopping the drug |
| Pre-operative pause before thymectomy | Per protocol | Many anaesthetists hold the morning dose to limit interaction with neuromuscular blocking agents during anaesthesia; coordinate with the surgical and neurology teams |
Both crises present with extreme muscle weakness that may include respiratory failure — the dose of pyridostigmine alone does not distinguish them. Cholinergic crisis (overdose) is suggested by accompanying muscarinic features: hypersalivation, lacrimation, defaecation, urinary urgency, miosis, sweating, abdominal cramps, bradycardia, bronchorrhoea, fasciculations. Myasthenic crisis (relative under-treatment / disease worsening) lacks these features; pupils are normal or dilated and secretions are not increased. The historical edrophonium (Tensilon) test referenced in the Mestinon FDA PI is no longer routinely used in the United States — edrophonium was withdrawn commercially and modern practice relies on clinical assessment, treating both as respiratory emergencies that require admission, airway support, and urgent specialist neurology / critical care consultation. Do not empirically increase the pyridostigmine dose in a deteriorating patient until cholinergic crisis has been excluded.
Drug Interactions
Pyridostigmine has relatively few classical metabolic drug interactions because it is not metabolised through the major CYP450 pathways. The clinically important interactions are predominantly pharmacodynamic — additive cholinergic effects, antagonism by anticholinergics, and complex effects at the neuromuscular junction during anaesthesia. The interactions below are drawn from the FDA prescribing information for pyridostigmine 105 mg extended-release (Section 7) and from major reference databases (Lexicomp, Micromedex).
Monitoring
Pyridostigmine therapy is symptom-led. Most monitoring is clinical — observing for symptom control, cholinergic side effects, and disease activity. The most important laboratory parameter is renal function (because clearance is largely renal); structured myasthenia gravis assessment (MG-ADL, QMG, or MG-QoL15) is helpful in chronic management but is performed by neurology rather than at routine pharmacy follow-up.
-
Symptom Control (MG)
Every visit; daily diary in unstable disease
Routine Track ptosis, diplopia, dysarthria, dysphagia, limb fatigability, respiratory function, and the timing of symptoms relative to doses. Use a structured tool (e.g., MG-ADL) where feasible. Disease fluctuation often requires dose timing adjustments rather than total-daily-dose changes. -
Cholinergic Side Effects
Every visit
Routine Ask specifically about diarrhoea, abdominal cramping, increased salivation/lacrimation, urinary frequency, sweating, fasciculations, and visual disturbance. Significant or escalating symptoms suggest dose reduction. -
Renal Function
Baseline; periodically; with new symptoms
Routine Creatinine and eGFR. Pyridostigmine is largely renally cleared; deterioration in renal function may unmask cholinergic toxicity at a previously stable dose. The FDA PI explicitly recommends careful dose selection and renal-function monitoring in renal impairment and elderly patients. -
Heart Rate
Each clinical assessment
Routine Mean reduction of 4–6 bpm in controlled study; symptomatic bradycardia is uncommon at therapeutic doses but the risk rises with concomitant beta-blockers, opioids, or sick sinus syndrome. -
Respiratory Status (MG)
During exacerbations or with new weakness
Trigger-based Spirometry (FVC, NIF) and pulse oximetry; deterioration may herald myasthenic crisis and need for plasma exchange / IVIG / ICU care. Severe cholinergic toxicity can produce identical respiratory failure — distinguish carefully before changing dose. -
Skin
Each visit
Trigger-based Bromide rash is uncommon but recognised; usually resolves with discontinuation. Document any new rash that appears after initiation. -
Train-of-Four (Reversal)
During and after Regonol bolus
Routine Use a peripheral nerve stimulator to confirm adequacy of reversal of nondepolarising neuromuscular blockade; the FDA Regonol PI explicitly recommends this. Continue ventilation until clinical recovery is confirmed. -
Pregnancy / Breastfeeding Plans
At initiation and as relevant
Trigger-based Pyridostigmine is generally continued through pregnancy in women with MG; breastfed infants of mothers on pyridostigmine had undetectable plasma drug levels in limited data. Multidisciplinary planning with neurology and obstetrics is appropriate.
Contraindications & Cautions
Absolute Contraindications
- Mechanical intestinal obstruction — increased peristalsis can precipitate perforation (per Mestinon, Regonol, and PB ER labels)
- Mechanical urinary obstruction — bladder stimulation against an obstruction can cause acute retention/upper-tract injury
- Known hypersensitivity to pyridostigmine, other anticholinesterase agents, or formulation excipients (per Regonol and PB ER labels; Mestinon label notes “particular caution” for the bromide moiety in sensitive patients)
Relative Contraindications (Specialist Input Recommended)
- Bronchial asthma — increased bronchial secretions and possible bronchoconstriction; the Mestinon FDA PI specifies “particular caution” in this group
- Chronic obstructive pulmonary disease — same rationale as asthma
- Bradyarrhythmias (sick sinus syndrome, second/third-degree AV block, post-MI conduction disease)
- Concurrent therapy with high-dose corticosteroids — risk of severe transient weakening of MG; specialist supervision essential
- Concomitant beta-blockers — additive negative chronotropy
- Bromide sensitivity — risk of rash; Mestinon and PB ER labels both flag this
- Significant renal impairment — dose reduction and cautious titration required
Use with Caution
- Recent gastrointestinal surgery — anastomotic risk from increased peristalsis.
- Glaucoma — particularly if patient already on cholinergic eye drops (additive effect; see Drug Interactions).
- Pregnancy — case reports and series with pyridostigmine have not identified an increased risk of major birth defects, miscarriage, or other adverse outcomes (FDA PI Section 8.1). MG itself can worsen during pregnancy and pyridostigmine is generally continued under specialist supervision.
- Lactation — pyridostigmine is present in human milk in small amounts, but in limited data was undetectable in the plasma of breastfed infants of mothers taking the drug (FDA PI Section 8.2).
- Pediatric MG — FDA labels state safety and effectiveness have not been established. Specialist-supervised off-label use is standard practice in juvenile and congenital MG, typically using the oral solution.
After exposure to soman, use atropine and pralidoxime. Pyridostigmine bromide alone will not protect against soman exposure. Its efficacy depends on the rapid use of atropine and pralidoxime (2-PAM) after exposure.
Always use protective garment(s). The primary protection against chemical nerve agents is wearing protective garments designed for this purpose, including a mask, hood, and overgarment.
Use pyridostigmine bromide as pretreatment only. The drug must not be taken after exposure to soman. If taken immediately before exposure (e.g., when the gas attack alarm is given) or at the same time as soman poisoning, it is not expected to be effective and may exacerbate the effects of a sub-lethal exposure.
This boxed warning applies only to the 105 mg extended-release tablet labelled for U.S. military use; it does not apply to Mestinon or Regonol formulations used for myasthenia gravis or neuromuscular block reversal.
Patient Counselling
Purpose of Therapy
For most patients, pyridostigmine is taken long-term for myasthenia gravis. Explain in plain language that the medicine improves muscle strength by raising the level of acetylcholine — the chemical messenger between nerve and muscle — at the neuromuscular junction. It does not treat the underlying autoimmune cause of myasthenia gravis (that is the role of immune-modulating therapies such as corticosteroids, azathioprine, mycophenolate, rituximab, or the newer FcRn and complement inhibitors). The dose is highly individual; the goal is enough strength to function comfortably without troublesome cholinergic side effects.
How to Take
For immediate-release tablets and oral solution, dose timing matters as much as the total daily amount. Take a dose 30–60 minutes before meals if chewing or swallowing is impaired, and before activities that demand strength. Do not double a dose that has been missed; if the next dose is due soon, simply skip the missed one. Swallow Timespan (180 mg ER) tablets whole — do not crush or chew, as this destroys the slow-release mechanism. Keep tablets in their original container with the silica gel packet — pyridostigmine tablets are hygroscopic.
Sources
- Mestinon® (pyridostigmine bromide) Tablets, Oral Solution, and Timespan® Tablets — US Prescribing Information. Bausch Health US, LLC. Revised December 2020. drugs.com/pro/mestinon.html Primary FDA label for the chronic oral formulations used in myasthenia gravis; source of the dosing range, contraindications, and qualitative adverse-effect profile cited in this monograph.
- Pyridostigmine Bromide Extended-Release Tablets (105 mg) — US Prescribing Information. Amneal Specialty (a division of Amneal Pharmaceuticals LLC). Revised October 2024 (Reference ID 5457129). accessdata.fda.gov Modern FDA label for the U.S. military soman-pretreatment formulation; source of the controlled-trial Table 1 frequency data, pharmacokinetic values (t½, Vd, clearance, anephric data, geriatric data), and the boxed warning summarised in this monograph.
- Regonol® (pyridostigmine bromide injection, USP) — US Prescribing Information. Sandoz Inc. dailymed.nlm.nih.gov FDA label for the IV formulation used as a reversal agent for nondepolarising neuromuscular blockade; source of the IV dosing approach, benzyl-alcohol caution, and peripheral-nerve-stimulator monitoring recommendation.
- Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021 Jan 19;96(3):114-122. doi: 10.1212/WNL.0000000000011124. PMID: 33144515. doi.org/10.1212/WNL.0000000000011124 International consensus statement that positions pyridostigmine as the first-line symptomatic therapy in autoimmune MG and provides guidance on combination with immunosuppressive therapy and special situations (pregnancy, ocular MG, MuSK-positive disease). Verify the most recent edition at time of publication — the consensus is periodically updated.
- Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther. 1980 Jul;28(1):78-81. doi: 10.1038/clpt.1980.134. PMID: 6993086. pubmed.ncbi.nlm.nih.gov/6993086 Foundational IV pharmacokinetic study cited in the Mestinon FDA PI: in patients with normal renal function (n = 5), the elimination half-life was 112 ± 12 min and serum clearance 9 ± 2 mL/kg/min; in anephric patients (n = 4), half-life rose to 379 ± 162 min and clearance fell to 2 ± 0.6 mL/kg/min — renal function accounts for ~ 75% of pyridostigmine clearance. The 2024 FDA PI rounds these findings to “elimination half-life increased 3-fold and systemic clearance decreased by 75%”.
- Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985 May;37(5):495-501. doi: 10.1038/clpt.1985.78. PMID: 3987173. pubmed.ncbi.nlm.nih.gov/3987173 Comparative IV (4 mg) and oral (60 mg) PK study cited in the Mestinon FDA PI. Oral bioavailability 11.5–18.9% (mean 14.3%); mean t½ after oral dosing was 200 min (~3.3 h), approximately twice the IV terminal t½ of 97 min. Note: the Mestinon PI lists this reference with the volume number “5” — this appears to be a typographical error in the label; the actual Clin Pharmacol Ther volume for May 1985 is 37, as confirmed by PubMed.
- Osserman KE, Genkins G. Studies in myasthenia gravis: reduction in mortality rate after crisis. JAMA. 1963;183:97-101. pubmed.ncbi.nlm.nih.gov/14048371 Historical reference cited in the Mestinon FDA PI for the differentiation of myasthenic and cholinergic crisis and the rationale for prompt withdrawal of anticholinesterase therapy in cholinergic crisis.
- Pyridostigmine. Drugs and Lactation Database (LactMed®). National Library of Medicine, Bethesda (MD). ncbi.nlm.nih.gov/books/NBK500999 Lactation safety summary that aligns with the FDA PI position: pyridostigmine is present in human milk in small amounts but generally undetectable in breastfed infant plasma; not considered a contraindication to breastfeeding under specialist supervision.
- Pyridostigmine Bromide Extended-Release Tablets, Sections 8.1–8.6 (Use in Specific Populations) and 12.3 (Pharmacokinetics). Amneal Specialty. Revised October 2024. accessdata.fda.gov Primary source for the modern pregnancy, lactation, paediatric, geriatric, and renal-impairment statements and the food-effect data on the 105 mg ER formulation.
- Raj SR, Black BK, Biaggioni I, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111(21):2734-2740. doi.org/10.1161/CIRCULATIONAHA.104.497594 Small randomised crossover study demonstrating acute reduction in standing heart rate with pyridostigmine 30 mg in patients with POTS; foundational evidence for the off-label POTS use cited in this monograph.